当前位置: 首页? 政策法规? 国外法规? 欧盟拒绝批准姜黄素、碳水化合物和蛋白的比例、Stablor@等的健康声称

欧盟拒绝批准姜黄素、碳水化合物和蛋白的比例、Stablor@等的健康声称

扫描二维 分享好友和朋友圈
放大字体缩小字体2018-10-27 01:13:50 来源9a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2018.261.01.0006.01.ENG&toc=OJ:L:2018:261:TOC" target="_blank" rel="nofollow">欧盟委员伙/a> 浏览次数9span id="hits">5768
核心提示:欧盟拒绝授权某些食品的健康声称,其中包?.拒绝批准添加Stablor?有助于减少内脏脂肪,同时维持超重或肥胖受试者的体的健康声称?.拒绝批准姜黄素有助于维持关节的正常功能;3.拒绝批准碳水化合物和蛋白的比例小于等?.8,并坚持12周有助于降低体重?.拒绝批准Vibigaba有助于维持体重、维持血糖水平、维持血压和维持胆固醇含量的健康声称、/div>
发布单位
欧盟委员
欧盟委员伙/div>
发布文号 Regulation (EU) 2018/1556
发布日期 2018-10-17 生效日期 2018-11-07
有效性状?/th> 废止日期 暂无
属?/th> 法规 专业属?/th> 标签标识
备注 欧盟拒绝授权某些食品的健康声称,其中包括1.拒绝批准添加Stablor?有助于减少内脏脂肪,同时维持超重或肥胖受试者的体的健康声称?.拒绝批准姜黄素有助于维持关节的正常功能;3.拒绝批准碳水化合物和蛋白的比例小于等?.8,并坚持12周有助于降低体重?.拒绝批准Vibigaba有助于维持体重、维持血糖水平、维持血压和维持胆固醇含量的健康声称、/td>
COMMISSION REGULATION (EU) 2018/1556

of 17 October 2018

refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods (1), and in particular Article 18(5) thereof,

Whereas:

(1)Pursuant to Regulation (EC) No 1924/2006 health claims made on foods are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.

(2)Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State. The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as the Authority, for a scientific assessment, as well as to the Commission and the Member States for information.

(3)The Authority is to deliver an opinion on the health claim concerned.

(4)The Commission is to decide on the authorisation of health claims taking into account the opinion delivered by the Authority.

(5)Following an application from Laboratoires Nutrition et Cardiomtabolisme, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Stablor?, a drink preparation with defined macro- and micronutrient composition and specific proportion of amino acids (tryptophan to neutral amino acids ratio) and decrease in visceral fat while preserving lean mass (Question No EFSA- Q-2016-00319 (2)). The claim proposed by the applicant was worded as follows: In the context of a well-balanced diet and a mild caloric restriction, the addition of Stablor? contributes to decrease visceral fat while preserving lean mass in overweight or obese subjects with abdominal fat and cardiometabolic risk factors.

(6)On 28 February 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of Stablor? and reduction of visceral fat while maintaining lean body mass in the context of an energy restricted diet. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

(7)Following an application from Suomen Terveysravinto Oy, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to curcumin and normal functioning of joints (Question No EFSA- Q-2016-00856 (3)). The claim proposed by the applicant was worded as follows: Curcumin contributes to the normal functioning of joints.

(8)On 8 May 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of curcumin and the maintenance of joint function. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

(9)Following an application from Marks and Spencer PLC, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to a carbohydrate:protein (CHO:P) ratio 1.8 on an energy basis in the context of an energy-restricted diet and body weight (Question No EFSA-Q-2016-00436 (4)). The claim proposed by the applicant was worded as follows: Helps to achieve a reduction in body weight and body fat when consumed as part of an energy restricted diet (< 8,368 kJ/2,000 kcal/day) for a minimum of 12 weeks.

(10)On 13 June 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of a CHO:P ratio 1.8 on an energy basis consumed in the context of an energy-restricted diet and the reduction of body weight. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

(11)Following an application from Loc Troi group, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Vibigaba (germinated brown rice) and reduction of body weight in the context of an energy-restricted diet (Question No EFSA- Q-2017-00032 (5)). The claim proposed by the applicant was worded as follows: In the context of an energy-restricted diet contributes to weight loss.

(12)On 21 July 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of Vibigaba (germinated brown rice) and the reduction of body weight in the context of an energy-restricted diet. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

(13)Following an application from Loc Troi group, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Vibigaba (germinated brown rice) and maintenance of long-term normal blood glucose concentration (Question No EFSA- Q-2017-00033 (6)). The claim proposed by the applicant was worded as follows: Contributes to the maintenance of normal blood glucose levels.

(14)On 21 July 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of Vibigaba (germinated brown rice) and the maintenance of long-term normal blood glucose concentration. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

(15)Following an application from Loc Troi group, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Vibigaba (germinated brown rice) and contribution to the maintenance of normal blood pressure (Question No EFSA- Q-2017-00031 (7)). The claim proposed by the applicant was worded as follows: Contributes to the maintenance of normal blood pressure.

(16)On 21 July 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of Vibigaba (germinated brown rice) and the maintenance of normal BP. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

(17)Following an application from Loc Troi group, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Vibigaba (germinated brown rice) and contribution to the maintenance of normal blood cholesterol concentration (Question No EFSA- Q-2017-00030 (8)). The claim proposed by the applicant was worded as follows: Contributes to the maintenance of normal blood cholesterol levels.

(18)On 21 July 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of Vibigaba (germinated brown rice) and maintenance of normal blood cholesterol concentration. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

(19)The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

HAS ADOPTED THIS REGULATION:

Article 1

The health claims listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 17 October 2018.

For the Commission

The President

Jean-Claude JUNCKER


(1) OJ L 404, 30.12.2006, p. 9.

(2) EFSA Journal 2017;15(2):4723.

(3) EFSA Journal 2017;15(5):4774.

(4) EFSA Journal 2017;15(6):4839.

(5) EFSA Journal 2017;15(7):4915.

(6) EFSA Journal 2017;15(7):4916.

(7) EFSA Journal 2017;15(7):4914.

(8) EFSA Journal 2017;15(7):4913.


ANNEX

Rejected health claim

Application Relevant provisions of Regulation (EC) No 1924/2006

Nutrient, substance, food or food category

Claim

EFSA opinion reference

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data

Stablor?, a drink preparation with defined macro- and micronutrient composition and specific proportion of amino acids (tryptophan to neutral amino acids ratio)

In the context of a well-balanced diet and a mild caloric restriction, the addition of Stablor? contributes to decrease visceral fat while preserving lean mass in overweight or obese subjects with abdominal fat and cardiometabolic risk factors.

Q-2016-00319

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data

Curcumin

Curcumin contributes to the normal functioning of joints.

Q-2016-00856

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data

A carbohydrate:protein (CHO:P) ratio 1.8 on an energy basis in the context of an energy-restricted diet and body weight

Helps to achieve a reduction in body weight and body fat when consumed as part of an energy restricted diet (< 8 368 kJ/2 000 kcal/day) for a minimum of 12 weeks.

Q-2016-00436

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data

Vibigaba (germinated brown rice)

In the context of an energy-restricted diet contributes to weight loss.

Q-2017-00032

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data

Vibigaba (germinated brown rice)

Contributes to the maintenance of normal blood glucose levels.

Q-2017-00033

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data

Vibigaba (germinated brown rice)

Contributes to the maintenance of normal blood pressure.

Q-2017-00031

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data

Vibigaba (germinated brown rice)

Contributes to the maintenance of normal blood cholesterol levels.

Q-2017-00030


Top
地区9/font>欧盟
标签9/font>含量蛋白健康声称
食品伙伴网提供标准法规解读、舆情监控、合规咨询、申报注册等服务、br/>电询?535-2129301
QQ?891238009
食品标法? border=
实时把握 食品标法动?/span>
请扫码关?span class="color2">食品标法圇/span>

声明9/p>

凡本网所有原?编译文章及图片、图表的版权均属食品伙伴网所有,如要转载,需注明“信息来源:食品伙伴网”、br> 凡本网注明“信息来源:XXX(非食品伙伴网)”的作品,均转载自其他媒体,转载目的在于传递更多的信息,并不代表本网赞同其观点和对其真实性负责、br> 邮箱:law#www.sqrdapp.com(发邮件时请?换成@ QQ?39307733

[ 政策法规搜索] [ 加入收藏] [ 告诉好友] [ 打印本文] [ 关闭窗口]

Baidu
map